Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;8(5):728-730.
doi: 10.21037/tlcr.2019.04.18.

First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?

Paul Hofman  1   2   3
Affiliations
Editorial

First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?

Paul Hofman. Transl Lung Cancer Res. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: P Hofman is a member of different industrial scientific advisory boards (Roche, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Merck, MSD, Qiagen, Thermofischer, Biocartis) for which he receives honorarium

Comment on

References

    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, et al. KEYNOTE-024 Investigators Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol 2019;37:537-46. 10.1200/JCO.18.00149 - DOI - PubMed
    1. Vigliar E, Malapelle U, Iaccarino A, et al. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. J Clin Pathol 2019. [Epub ahead of print]. 10.1136/jclinpath-2019-205732 - DOI - PubMed
    1. Expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%). Accessed April 11, 2019. Available online: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm635857.htm...
    1. Lopes G, Wu YL, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018;36:LBA4 10.1200/JCO.2018.36.18_suppl.LBA4 - DOI